Literature DB >> 9063527

Immunohistochemistry of complement response on human renal cell carcinoma biopsies.

T Magyarlaki1, S Mosolits, F Baranyay, I Buzogány.   

Abstract

The goal of the study was to characterize the complement humoral and cellular antitumor responses on primary renal cell carcinoma biopsies. As an original observation, complement activation was found on 11/22 cases. Classical complement pathway activation was characterized by tumor C1q complement protein and IgG deposition (5/22 cases). Alternative or nonimmune complement pathway activation was seen as tissue deposition of C3 (6/22 cases). The membrane attack complex was present in cases with alternative complement pathway activation at the sites of tumor necrosis. Renal cell carcinomas with complement activation overexpressed at least one of the complement regulatory factors (membrane cofactor protein, decay accelerating factor, membrane attack complex inhibitor) and major histocompatibility complex class II molecules. Tumor infiltrating lymphocytes were present in most of the renal cell carcinomas with complement activation (8/11). However, the number of tumor-infiltrating lymphocytes was correlated with the intensity of major histo-compatibility complex-II expression in 18/22 cases. Detection of complement activation and immune cell infiltrates on renal cell carcinoma primary biopsies may serve as a new predictive factor for immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9063527     DOI: 10.1177/030089169608200513

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  7 in total

1.  Prognostic histological and immune markers of renal cell carcinoma.

Authors:  T Magyarlaki; I Buzogány; L Kaiser; F Sükösd; R Döbrönte; B Simon; A Fazekas; J Nagy
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

2.  Specific von Hippel-Lindau protein expression of clear cell renal cell carcinoma with "immunogenic" features.

Authors:  T Magyarlaki; I Buzogány; J Nagy
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

3.  Ascitic complement system in ovarian cancer.

Authors:  L Bjørge; J Hakulinen; O K Vintermyr; H Jarva; T S Jensen; O E Iversen; S Meri
Journal:  Br J Cancer       Date:  2005-03-14       Impact factor: 7.640

Review 4.  Immune consequences of anti-angiogenic therapyin renal cell carcinoma.

Authors:  Klaudia K Brodaczewska; Cezary Szczylik; Claudine Kieda
Journal:  Contemp Oncol (Pozn)       Date:  2018-03-05

Review 5.  Deposition of the Membrane Attack Complex in Healthy and Diseased Human Kidneys.

Authors:  Jacob J E Koopman; Mieke F van Essen; Helmut G Rennke; Aiko P J de Vries; Cees van Kooten
Journal:  Front Immunol       Date:  2021-02-11       Impact factor: 7.561

6.  Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma.

Authors:  Rossen M Donev; Lisa C Gray; Baalasubramanian Sivasankar; Timothy R Hughes; Carmen W van den Berg; B Paul Morgan
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

7.  Elevated expression of SLC34A2 inhibits the viability and invasion of A549 cells.

Authors:  Weihan Yang; Yu Wang; Qiang Pu; Sujuan Ye; Qingping Ma; Jiang Ren; Guoxing Zhong; Lunxu Liu; Wen Zhu
Journal:  Mol Med Rep       Date:  2014-07-14       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.